4523 Eisai
- 5768.0
- -860.0-12.98%
Eisai News
Eisai: Latest information on the regulatory review of Leconemab for early Alzheimer's disease in the European Union.
Eisai: Regarding the approval review status of Lecanemab in the EU.
Eisai: Eisai has announced the transition to developing and commercializing the Farletsuzumab Ecteinascidin-1 Antibody Drug Complex (ADC) on its own.
Eisai: Regarding the antibody drug complex farletuzumab ecteribulin (FZEC), Eisai will transition to global development and commercialization on its own.
Eisai: Eisai announces the status of acquiring treasury stock.
Eisai: Position and policy regarding reduction of investment unit in company's stock.
Eisai: Considerations and policies regarding the reduction of investment units.
Eisai: Eisai announces the appointment of company executives and directors.
Eisai: Company executives at Eisai Co., Ltd.
Eisai: Eisai Announces Status Regarding Repurchase of Own Shares
Eisai: Independent Officer Notification Form
Eisai: FY2023 (ended 2024/3/31) full-year financial results reference data
Eisai: Consolidated financial report for fiscal year 2023 (year ended March 31, 2024) [IFRS]
Eisai: Eisai announces repurchase of treasury stock and cancellation of treasury stock
Eisai: Notice regarding candidates for directors and executive officers
Eisai: Notice regarding the appointment of new representative officers
Eisai: Notice regarding the election of candidates for directors and candidates for executive officers
Eisai: Statutory ex post facto disclosure documents (mergers and acquisitions) (Kan Laboratories Co., Ltd.)
Eisai: Notice of the Settlement of Patent Infringement Litigation Related to Lenvatinib in the U.S.
Eisai: Settlement of patent infringement lawsuits relating to lenvatinib in the United States
Analysis
Price Target
No Data
